Dr. Alexander Guminski
Claim this profileRoyal North Shore Hospital
Area of expertise
Transitional Cell Carcinoma
Alexander Guminski has run 2 trials for Transitional Cell Carcinoma. Some of their research focus areas include:
Bladder Cancer
Alexander Guminski has run 2 trials for Bladder Cancer. Some of their research focus areas include:
Clinical Trials Alexander Guminski is currently running
Disitamab Vedotin + Pembrolizumab vs Chemotherapy
for Bladder Cancer
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease. Participants in this study will have cancer that has spread through the body (metastatic) or spread near where it started (locally advanced). In this study, there are 2 different groups. Participants will be assigned to a group randomly. Participants in the disitamab vedotin arm will get the study drug disitamab vedotin once every two weeks and pembrolizumab once every 6 weeks. Participants in the standard of care arm will get gemcitabine once a week for 2 weeks with either cisplatin or carboplatin once every 3 weeks.
Recruiting
2 awards
Phase 3
BEP Chemotherapy
for Germ Cell Cancer
The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumours.
Recruiting
2 awards
Phase 3
6 criteria
More about Alexander Guminski
Clinical Trial Related
2 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Alexander Guminski has experience with
- Cisplatin
- Bleomycin Sulfate
- Etoposide
- Filgrastim
- Pegfilgrastim
- Avelumab
Breakdown of trials Alexander Guminski has run
Transitional Cell Carcinoma
Bladder Cancer
Germ Cell Tumors
Urothelial Carcinoma
Immunotherapy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alexander Guminski specialize in?
Alexander Guminski focuses on Transitional Cell Carcinoma and Bladder Cancer. In particular, much of their work with Transitional Cell Carcinoma has involved Stage IV patients, or patients who are Stage III.
Is Alexander Guminski currently recruiting for clinical trials?
Yes, Alexander Guminski is currently recruiting for 2 clinical trials in St Leonards New South Wales. If you're interested in participating, you should apply.
Are there any treatments that Alexander Guminski has studied deeply?
Yes, Alexander Guminski has studied treatments such as Cisplatin, Bleomycin Sulfate, Etoposide.
What is the best way to schedule an appointment with Alexander Guminski?
Apply for one of the trials that Alexander Guminski is conducting.
What is the office address of Alexander Guminski?
The office of Alexander Guminski is located at: Royal North Shore Hospital, St Leonards, New South Wales 2065 Australia. This is the address for their practice at the Royal North Shore Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.